GC – Gastric carcinoma
Introduction
In October 2021, the EMA granted marketing authorization for nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for HER2-negative advanced or metastatic gastric adenocarcinoma in patients whose tumors express PD-L1 CPS ≥5.
Accordingly, we will be calculating CPS ≥5 for this entity as well in the future.
At the moment, this makes nivolumab the only checkpoint inhibitor for which evaluating PD-L1 as a biomarker is a prerequisite for the entity gastric carcinoma.
Data protection and the German Drug Advertising Act (HWG) require that the professional affiliation of the portal visitors. The complete page with all contents is only available to medical personnel.
You can login with DocCheck, you QuIP-Account or Access-Code.
Login with QuIP-Account
Please enter your user name (e-mail address) and the corresponding password, which you also need for your login to the ring trial portal www.quip.eu can be used.
Login with Access-Code
Please enter your personal code, which you have already received by voucher.